
Patrys
PAB.AXPatrys Limited Price (PAB.AX)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
2,055,750,235
(0.0169)%Description
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; an... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $0.002-0.01
- Market Cap 4.11M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Dr. James A. Campbell B.Sc., MBA, Ph.D.
- IPO Date: July, 13, 2007
- Country: AU
- Currency: AUD
- Headquaters: Melbourne, VIC
- Employees: 15
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
